Injection means for hemocorrection

 

(57) Abstract:

The invention relates to medicine, in particular to pharmacology and pharmacy and concerns the means for the correction of disorders in the disorders caused by various factors. The proposed tool, containing the sodium salt of DNA and pharmaceutically adequate solvent in certain ratios. The tool stimulates blood and Mylopotas, does not cause complications. 3 table.

The invention relates to medicine, in particular to pharmacology and formations and relates to means for correcting haematopoiesis at its disorders caused by various factors (chemoradiation therapy, ionizing radiation, and so on).

The Arsenal of tools used for depression of making blood is quite diverse [1-7] Using bone marrow transplantation, lakomski, colony stimulating factors, and among pharmaceuticals pentopril, zymosan, vitamins different groups [1,2,8] However, bone marrow transplantation is associated with extra traumatic intervention, and the introduction of lakomski can cause immune conflict [9-11] At the same time, drug therapy is not effective enough [2]

Known injection means for hemocorrection rawhide 2-5% solution over 5-10 ml intramuscularly.

However, injection of nucleinate sodium is extremely painful, and the range of its pharmacological activity is quite narrow and applies stimulation only leukocyte number [4-6] At the same time, numerous studies deoxyribonucleic acid and its salts has not resulted in adequate dosage forms [1,3]

The essence of the invention is that first proposed a means for hemocorrection containing powder of sodium salt belongs to low-polymeric DNA obtained from sturgeon milk, and pharmaceutically adequate solvent in the following ratios, wt.

Powder sodium salt belongs to low-polymeric DNA obtained from sturgeon milk, mol. wt. OF 0.3 TO 12.0 MD 1,0-2,0;

Pharmaceutically adequate solvent to 100.0

DNA in the form of powder get known method [8] of sturgeon milk. Target product has the following characteristics: mol. wt.

0,3-12, 0mm; hyperchromic effect /G/ 37-46% of the protein content of not more than 1.5% by weight RNA not more than 6% polysaccharides not more than 2%

The molar ratio of nucleotides:

Adenine 29,0

Thymine 27,0

Guanine 22,0

Cytosine 20,0

The essential features of the proposal should be considered quantitative composition is of GLA. 1).

Thus, PL. 1 illustrates the optimality of the quantitative composition of the funds.

Preparation of funds is carried out in the factory traditional volume-weight method 7[2] to a certain weight amount of powder DNA add solvent to obtain the desired volume of solution. Next, the solution is filtered, sterilized, dispensed into vials of 5 and 10 ml. solvent used distilled water or saline solution. The resulting solution is a clear liquid that contains no mechanical or other impurities, stable. May be stored for a long time. When the chemical and bacteriological pollution control is not revealed. Meets the requirements GPH.

In experimental and clinical studies have revealed gemokorrektsi property funds. The experiments were conducted on mice hybrids F1(CBAXC57B1the males weighing 16-20, the Cytopenia caused by the introduction of cyclophosphamide intraperitoneally once in doses of 200 and 275 mg/kg of the Sodium salt of DNA was injected subcutaneously once in equicharacteristic doses, and at 3, 5, 7 days after the second blood using the camera Goryaeva. The results of the experiment are presented in table. 2.

As can be seen from the results shown in table. 2, the maximum cytopenic effect with the introduction of cyclophosphamide developed by the 3rd day, the restoration of the number of cells marked for 7-9 days. However, at 12-13 days there is a second, less profound reduction in the number of leukocytes. With the introduction of DNA at 3, 5 and 7 day maximum stimulating effect. And after 2-3 days after the first injection of DNA the number of cells is returned to the background level before the introduction of cyclophosphamide, and by the 7th-10th days the number of cells reaches the maximum value exceeding this level. It is important to note that unlike other hemocorrection, DNA does not cause compensatory drop in the number of cells after emotially.

In General, the analysis of experimental data allows to draw the following conclusions:

1. Unlike the prototype for the use of funds are:

the rapid recovery of the number of leukocytes in peripheral blood;

the increase in the number of kariolou in the bone marrow.

2. To obtain the stimulating effect of a single injection of DNA, while the TES tool unlike the prototype does not cause compensatory decrease the number of cells after emotially.

4. When you use the no identified side effects and complications.

The clinic was conducted by research funds in cancer patients with depression of haematopoiesis through the use of chemoradiation therapy (resolution of the Pharmacological Committee attached). As a result of treatment with cytostatics and radiation exposure in the treatment group developed leukopenia from 100 to 1500 mm3blood. After the introduction of the funds rate 1-2 times depending on the severity of the process there was an increase in the number of cells in 3-4 times. Analysis myelogram showed that the introduction of the funds has a positive impact not only on leucopoiesis, but all megakaryocyte blood.

Example. Patient K. about mielodepressii caused by chemo-radiotherapy was carried out by the introduction of a 1.5% aqueous solution of sodium salt of DNA in an amount of 5 ml, obtained by the above method with the following characteristics DNA: molecular weight of 0.3 to 12.0; hyperchromic effect /G/ 37-46% of the protein content of not more than 1.5% by weight RNA not more than 6% polysaccharides not more than 2%

The molar ratio of nucleotides:

Adenine 29,0

Thymine 27,0

Guanine 22 who observed a gradual increase in the number of leukocytes. So on the first day after the injection of 700 mm3blood in the 2 day 1000, 4200 in 3 day, 5 day 5100. Also characterized by positive dynamics of all cells of the granulocytic Rostock, the number of which increased from 47 to 52.5% (average 57%). Index of maturation of eritrotsitov stated before treatment means equal to zero, after treatment of 0.8% (normal range 0.7 to 0.9).

Complications of a General nature, as well as irritation or pain at the injection site was not detected.

Thus, the example illustrates the effectiveness of the funds as of the preparation for hemocorrection, as well as the optimality of its quantitative composition.

Comparison of stated funds from the prototype are presented in table. 3.

Thus, the claimed means compared to the prototype has a wider range of actions, including effects not only on leucopoiesis, but also on bone marrow hematopoiesis. The tool does not cause General and local complications. Now even at 1-2 times the introduction.

All this allows to recommend it for General use as proofreading of hemopoiesis in all cases of its violation.

References:

1. Belous A. M. Exogenous nucleic what about - and hormonal therapy of malignant tumors. -M. Medicine, 1982, S. 98-142.

3. Loginov A. S. and other Reparative effects of drugs nucleic acid in experimental gastric ulcer. -Bull. exp. Biol. and the honey. 1991, No. 7, S. 59-60.

4. Mashkovsky M. D. Medicines. -M. Medicine, 1985, so 2, S. 172.

5. Register of medicines of Russia. M Interforum, 1993, S. 603.

6. Rychnov C. that is, Nucleic acids and their therapeutic application. - Medical business, 1981, No. 8, S. 114-118.

7. Kharkevich D. A. and other General formulation. M. Medicine, 1971, S. 54-64.

8. The application of the applicant organization N 93020155 "a Method for DNA extraction from sturgeon milk" from 24.05.93.

9. M. Begni, S. Siena Breakthrough in cytokine therapy; an overview of GM-CSF, Royal Society of Medicine Serwices gnt. Congress and Symposium Series, 1992, No. 170, p. 1-6.

10. P. Gupta et all. Bone Marrow Transplantation 1992, N 9, p. 491-492.

11. P. Riikonen, V., Saarinen'an Medical Pediatric Oncology 1992, N 20, p. 489-496.

Injection means for hemocorrection, containing as the active ingredient sodium salt belongs to low-polymeric DNA and a pharmaceutically acceptable carrier, characterized in that as the active ingredient it contains a powder, a mixture of DNA with a molecular mass of 0.3 to 12.0 MD and not more than 6% of the RNA in the following ratio, wt.


 

Same patents:
The invention relates to biotechnology, molecular biology, medical diagnostics and can be used to identify the studied biological material, in particular when hybridization analysis of nucleic acids, including viral, using the detector avidin-bitenova (streptavidin-bitenova) system

The invention relates to the microbiological industry, and can be used for medical preparations

The invention relates to the field of Bioorganic chemistry and can be used in molecular biology, genetic engineering and medicine
The invention relates to the field of medicine and for the treatment of disorders of haematopoiesis

The invention relates to the chemistry of biologically active compounds, specifically to an improved method for producing a sterile solution of native sodium salt of deoxyribonucleic acid, which can find application in medical practice, pharmaceutical industry, biochemistry, cosmetics and perfumes

The invention relates to the chemistry of biologically active substances, particularly to a method of producing powder of sodium salt of deoxyribonucleic acid (DNA) from animal products, which may find application in medical practice, pharmaceutical industry, biochemistry, cosmetics and perfumes

The invention relates to medicine, specifically to produce new medicines, which can find application in medicine

The invention relates to medicine, namely to andrology

The invention relates to medicine, specifically to pharmacology

The invention relates to drugs lipid nature of the polyunsaturated fatty acids

FIELD: medicine.

SUBSTANCE: method involves carrying out hernia removal in intralaminar way. Posterior longitudinal ligament defect is covered with Tacho-Comb plate after having done disk cavity curettage. Subcutaneous fat fragment on feeding pedicle is brought to dorsal surface of radix and dural sac.

EFFECT: enhanced effectiveness of treatment; reduced risk of traumatic complications.

1 dwg

Up!